Dynamk Capital, a US-based venture capital firm, has raised $65m for its debut fund from limited partners including drugs maker Pfizer, and healthcare-focused JSR Group and Lonza.
The final close for the Dynamk Life Sciences Fund targets investments in the enabling tools, technologies and services for biopharma companies’ discovery, development and manufacturing needs.
Daniella Kranjac, founding partner at Dynamk, which has already backed RoosterBio and Envisagencis, said: “Life science industrials companies are at the foundation of today’s most important therapies.”
Before Dynamk, Kranjac had been global head for enterprise solutions at GE Healthcare.
